Nanobiosensors in Healthcare Market Research Report - Global Forecast till 2024

Nanobiosensors in Healthcare Market: Information by type (Optical Nanobiosensor, Electrochemical Nanobiosensor, Acoustic Nanobiosensor), Application (Diabetes, Immunoassay, Cancer, Pathogenic Bacteria), End User (Hospitals and Clinics, Point of Care, Diagnostic Centers ) - Global Forecast till 2024

ID: MRFR/HC/6521-HCR | February 2021 | Region: Global | 85 pages

Market Scenario
Global Nanobiosensors in Healthcare Market is expected to register a CAGR of 9.84% from 2019 to 2024.
Nanotechnology in the biosensor is known as nanobiosensor; biosensors are analytical devices used for detection of chemical and biological substances in the human body. Nanobiosensors are the sensors that are made up of nanomaterials and have dimensions between 1 to 100 nanometers. Nanobiosensors are becoming popular in developed countries. The rising prevalence of diabetes in emerging economies, demand for advanced monitoring systems, and raising awareness about advance nanobiosensors are expected to drive the growth of the market. According to the International Diabetes Federation (IDF), it is estimated that the number of diabetic patients in the Middle East and North Africa (MENA) region will grow by 96% from the year 2013 to 2035, i.e., from 34.6 million to 67.9 million. Moreover, rising R&D spending and collaborative strategies adopted by the top players, such as new product launches and collaborations for product development are contributing to the growth of the market.
The rising cost of nanobiosensors and unfavorable reimbursement policies may hamper the growth of the market during the assessment period.
Nanobiosensors in Healthcare Market Segmentation
The global nanobiosensors in the healthcare market has been segmented on the basis of type, application, end user, and region.
On the basis of type, the market has been classified as optical nanobiosensors, electrochemical nanobiosensors, acoustic nanobiosensors, and others. Based on the application, the market has been segmented into diabetes, immunoassay, cancer, pathogenic bacteria, and others. The market, by end user, has been classified as hospitals and clinics, diagnostic centers, point of care, and others. The electrochemical nanobiosensors segment is expected to hold the largest market share of the nanobiosensors in healthcare market owing to its high sensitivity and real-time detection features. However, based on end user point of care testing segment holds the largest market share due to low complex infrastructure and training.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nanobiosensors in the healthcare market in the Americas has further been segmented into North America and South America, with the North America market further divided into the US and Canada.
The European nanobiosensors in the healthcare market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The nanobiosensors in healthcare market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The nanobiosensors in healthcare market in the Middle East & Africa has been segmented into the Middle East and Africa.
Nanobiosensors in Healthcare Market Key Players
Some of the key players in the global nanobiosensors in healthcare market are Abbott Point of Care, Inc., F. Hoffman-LA Roche Ltd., Medtronic Inc., Nano-Proprietary, Inc., Lifescan, Inc., Illuminex Corporation, Lifesensors, Inc., ACON Laboratories, Inc., Pharmaco-Kinesis Corporation, Bayer Healthcare AG, Bio-Rad Laboratories, Inc., Biosensors International Pte. Ltd., Sysmex Corporation.
Regional Market Summary
Global Nanobiosensors in Healthcare Market Share, by Region, 2018 (%)
 
Source: MRFR Analysis
The Americas are likely to dominate the global nanobiosensors in healthcare market owing to the rising prevalence of chronic disorders, initiative by government and regulatory authorities, and demands for advanced technology. According to the report published by the US Department of Health & Human Services, in 2017, around 11.5% of the adult population in the US are diagnosed with heart disease, i.e., 28.2 million.
The European market is expected to be the second largest nanobiosensors in healthcare market. The market growth in this region can be attributed to the government focus to control chronic disease, well-established healthcare infrastructure, and the rising population suffering from cardiovascular disorders. Moreover, government funding and support to the healthcare sector are also expected to boost the growth of the nanobiosensors in healthcare market during the forecast period. According to the European Heart Network, cardiovascular disorders are responsible for 3.9 million deaths in the European Union, which are 45% of the total deaths.
Asia-Pacific is expected to be the fastest-growing nanobiosensors in healthcare market during the forecast period owing to rising diabetes, increasing disposable income, and government initiatives for the development of the healthcare sector. According to the International Diabetes Federation, in 2017, more than 84 million people in South-East Asia were affected by diabetes, and this number is expected to reach 156 million by 2045. Moreover, the government of these countries is open to adopting new technology and the best treatment option from a developed country. According to the International Agency for Research on Cancer, in 2018, India has a prevalence of 173.5 cancer patients per 100,000 population. Moreover, in China, the prevalence rate of cancer was 377.6 patients per 100,000 population in 2018
The market in the Middle East & Africa is expected to hold the smallest share of the global nanobiosensors market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities
Global Nanobiosensors in Healthcare Market, by Type

Optical Nanobiosensors
Electrochemical Nanobiosensors
Acoustic Nanobiosensors
Others

Global Nanobiosensors in Healthcare Market, by Application

Diabetes
Immunoassay
Cancer
Pathogenic Bacteria
Others

Global Nanobiosensors in Healthcare Market, by End User

Hospitals & Clinics
Diagnostic Centre
Point of Care Testing
Others

Global Nanobiosensors in Healthcare Market, by Region

Americas

North America

US
Canada

Latin America

Europe

Western Europe

Germany
France
Italy
Spain
UK
Rest of Western Europe

Eastern Europe

Asia-Pacific

Japan
China
India
Australia
South Korea
Rest of Asia-Pacific

Middle East & Africa

Middle East
Africa

Intended Audience

Nano Biosensor manufacturers
Nano Biosensor distributors and suppliers
Healthcare providers
Research institutes and academic centers
Government associations
Market research and consulting



Frequently Asked Questions (FAQ) :


Nanobiosensors in healthcare market is projected to grow at a 9.84% CAGR between 2019-2024.

The Americas is expected to dominate the nanobiosensors in healthcare market.

Increasing prevalence of diabetes and awareness about advance nanobiosensors are the key factors driving the nanobiosensors in healthcare market.

Unfavorable reimbursement policies and rising cost may limit the nanobiosensors in healthcare market.

The electrochemical nanobiosensors segment will dominate the nanobiosensors in healthcare market.

Table of Contents:
Chapter 1 Report Prologue

Chapter 2 Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3 Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4 Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Detection Technique Trends & Assessment

Chapter 5 Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6 Global Nano Biosensors in Healthcare Market, by Type

6.1 Introduction

6.2 Optical Nanobiosensors

Market Estimates & Forecast, by Region, 2019–2024

Market Estimates & Forecast, by Country, 2019–2024

6.3 Electrochemical Nanobiosensors

Market Estimates & Forecast, by Region, 2019–2024

Market Estimates & Forecast, by Country, 2019–2024

6.4 Acoustic Nanobiosensors

Market Estimates & Forecast, by Region, 2019–2024

Market Estimates & Forecast, by Country, 2019–2024

6.5 Others

Chapter 7 Global Nano Biosensors in Healthcare Market, by Application

7.1 Introduction

7.2 Diabetes

Market Estimates & Forecast, by Region, 2019–2024

Market Estimates & Forecast, by Country, 2019–2024

7.3 Immunoassay

Market Estimates & Forecast, by Region, 2019–2024

Market Estimates & Forecast, by Country, 2019–2024

7.4 Cancer

Market Estimates & Forecast, by Region, 2019–2024

Market Estimates & Forecast, by Country, 2019–2024

7.5 Pathogenic Bacteria

Market Estimates & Forecast, by Region, 2019–2024

Market Estimates & Forecast, by Country, 2019–2024

7.6 Others

Market Estimates & Forecast, by Region, 2019–2024

Market Estimates & Forecast, by Country, 2019–2024

Chapter 8 Global Nano Biosensors in Healthcare Market, by End User

8.1 Introduction

8.2 Hospitals & Clinics

Market Estimates & Forecast, by Region, 2019–2024

Market Estimates & Forecast, by Country, 2019–2024

8.3 Diagnostic Centre

Market Estimates & Forecast, by Region, 2019–2024

Market Estimates & Forecast, by Country, 2019–2024

8.4 Point of Care Testing

Market Estimates & Forecast, by Region, 2019–2024

Market Estimates & Forecast, by Country, 2019–2024

8.5 Others

Market Estimates & Forecast, by Region, 2019–2024

Market Estimates & Forecast, by Country, 2019–2024

Chapter 9 Global Nano Biosensors in Healthcare Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 Latin America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Developments & Strategies

Chapter 11 Company Profiles

11.1 Abbott Point of Care, Inc.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financial Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.1.6 Key Strategies

11.2 F. Hoffman-LA Roche Ltd.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.2.6 Key Strategies

11.3 Medtronic Inc.

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Developments

11.3.5 SWOT Analysis

11.3.6 Key Strategies

11.4 Nano-Proprietary, Inc.

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Developments

11.4.5 SWOT Analysis

11.4.6 Key Strategies

11.5 Lifescan, Inc.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial Overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.5.6 Key Strategies

11.6 Illuminex Corporation

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.6.6 Key Strategies

11.7 Lifesensors, Inc.

11.7.1 Company Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.7.6 Key Strategies

11.8 ACON Laboratories, Inc.

11.8.1 Company Overview

11.8.2 Product Overview

11.8.3 Financial Overview

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.8.6 Key Strategies

11.9 Pharmaco-Kinesis Corporation

11.9.1 Company Overview

11.9.2 Product Overview

11.9.3 Financial Overview

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.9.6 Key Strategies

11.10 Bayer Healthcare AG

11.10.1 Company Overview

11.10.2 Product Overview

11.10.3 Financial Overview

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.10.6 Key Strategies

11.11 Bio-Rad Laboratories, Inc.

11.11.1 Company Overview

11.11.2 Product Overview

11.11.3 Financial Overview

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.11.6 Key Strategies

11.12 Biosensors International Pte. Ltd.

11.12.1 Company Overview

11.12.2 Product Overview

11.12.3 Financial Overview

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.12.6 Key Strategies

11.13 Sysmex Corporation

11.13.1 Company Overview

11.13.2 Product Overview

11.13.3 Financial Overview

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.13.6 Key Strategies

11.14 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Nano Biosensors in Healthcare Industry

Chapter 13 Appendix


LIST OF TABLES

Table 1 Global Nano Biosensors in Healthcare Market Synopsis, 2019–2024

Table 2 Global Nano Biosensors in Healthcare Market Estimates and Forecast, 2019–2024 (USD Million)

Table 3 Global Nano Biosensors in Healthcare Market, by Region, 2019–2024 (USD Million)

Table 4 Global Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)

Table 5 Global Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)

Table 6 North America: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)

Table 7 North America: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)

Table 8 US: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)

Table 9 US: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)

Table 10 Canada: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)

Table 11 Canada: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)

Table 12 Latin America: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)

Table 13 Latin America: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)

Table 14 Europe: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)

Table 15 Europe: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)

Table 16 Western Europe: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)

Table 17 Western Europe: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)

Table 18 Eastern Europe: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)

Table 19 Eastern Europe: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)

Table 20 Asia-Pacific: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)

Table 21 Asia-Pacific: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)

Table 22 Middle East & Africa: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)

Table 23 Middle East & Africa: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)
LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Nano Biosensors in Healthcare Market

Figure 3 Segmentation Market Dynamics for Global Nano Biosensors in Healthcare Market

Figure 4 Global Nano Biosensors in Healthcare Market Share, by Type, 2018

Figure 5 Global Nano Biosensors in Healthcare Market Share, by Application, 2018

Figure 6 Global Nano Biosensors in Healthcare Market Share, by Region, 2018

Figure 7 North America: Nano Biosensors in Healthcare Market Share, by Country, 2018

Figure 8 Europe: Nano Biosensors in Healthcare Market Share, by Country, 2018

Figure 9 Asia-Pacific: Nano Biosensors in Healthcare Market Share, by Country, 2018

Figure 10 Middle East & Africa: Nano Biosensors in Healthcare Market Share, by Country, 2018

Figure 11 Global Nano Biosensors in Healthcare Market: Company Share Analysis, 2018 (%)

Figure 12 Abbott Point of Care, Inc.: Key Financials

Figure 13 Abbott Point of Care, Inc.: Segmental Revenue

Figure 14 Abbott Point of Care, Inc.: Geographical Revenue

Figure 15 F. Hoffman-LA Roche Ltd.: Key Financials

Figure 16 F. Hoffman-LA Roche Ltd.: Segmental Revenue

Figure 17 F. Hoffman-LA Roche Ltd.: Geographical Revenue

Figure 18 Medtronic Inc.: Key Financials

Figure 19 Medtronic Inc.: Segmental Revenue

Figure 20 Medtronic Inc.: Geographical Revenue

Figure 21 Nano-Proprietary, Inc.: Key Financials

Figure 22 Nano-Proprietary, Inc.: Segmental Revenue

Figure 23 Nano-Proprietary, Inc.: Geographical Revenue

Figure 24 Lifescan, Inc.: Key Financials

Figure 25 Lifescan, Inc.: Segmental Revenue

Figure 26 Lifescan, Inc.: Geographical Revenue

Figure 27 Illuminex Corporation: Key Financials

Figure 28 Illuminex Corporation: Segmental Revenue

Figure 29 Illuminex Corporation: Geographical Revenue

Figure 30 Lifesensors, Inc.: Key Financials

Figure 31 Lifesensors, Inc.: Segmental Revenue

Figure 32 Lifesensors, Inc.: Geographical Revenue

Figure 33 ACON Laboratories, Inc.: Key Financials

Figure 34 ACON Laboratories, Inc.: Segmental Revenue

Figure 35 ACON Laboratories, Inc.: Geographical Revenue

Figure 36 Pharmaco-Kinesis Corporation: Key Financials

Figure 37 Pharmaco-Kinesis Corporation: Segmental Revenue

Figure 38 Pharmaco-Kinesis Corporation: Geographical Revenue

Figure 39 Bayer Healthcare AG: Key Financials

Figure 40 Bayer Healthcare AG: Segmental Revenue

Figure 41 Bayer Healthcare AG: Geographical Revenue

Figure 42 Bio-Rad Laboratories, Inc.: Key Financials

Figure 43 Bio-Rad Laboratories, Inc.: Segmental Revenue

Figure 44 Bio-Rad Laboratories, Inc.: Geographical Revenue

Figure 45 Biosensors International Pte. Ltd.: Key Financials

Figure 46 Biosensors International Pte. Ltd.: Segmental Revenue

Figure 47 Biosensors International Pte. Ltd.: Geographical Revenue

Figure 48 Sysmex Corporation: Key Financials

Figure 49 Sysmex Corporation: Segmental Revenue

Figure 50 Sysmex Corporation: Geographical Revenue



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.